Tailored Management of Advanced Esophageal Squamous Cell Carcinoma — Balancing Efficacy and Toxicity with a “Hold Chemotherapy and Keep Immunotherapy” Strategy: A Case Report
Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with a poor prognosis in advanced stages. Pivotal trials including ATTRACTION-3, CheckMate 648, and CheckMate 577 have demonstrated that immunotherapy with nivolumab significantly improved survival and maintained disease control....
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-04-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-25-00007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839638532599054336 |
|---|---|
| author | Yu-Chieh Lin Jeng-Shiun Du Chun-Chieh Wu |
| author_facet | Yu-Chieh Lin Jeng-Shiun Du Chun-Chieh Wu |
| author_sort | Yu-Chieh Lin |
| collection | DOAJ |
| description | Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with a poor prognosis in advanced stages. Pivotal trials including ATTRACTION-3, CheckMate 648, and CheckMate 577 have demonstrated that immunotherapy with nivolumab significantly improved survival and maintained disease control. We report a 59-year-old female with a 3-month history of intermittent nausea, vomiting, and unintentional weight loss of approximately 5 kg. A definite diagnosis of ESCC with distant lymph node metastasis (cT2N3M1, Stage IVB) was confirmed by positron emission tomography and esophagogastroduodenoscopy with biopsy. This report details her clinical course, including chemotherapy, immunotherapy, and radiation therapy. Despite initially achieving complete remission, recurrence was detected during follow-up. A ”Hold Chemotherapy and Keep Immunotherapy” strategy effectively managed advanced ESCC, balancing efficacy and toxicity while preserving quality of life. |
| format | Article |
| id | doaj-art-9dd59809a1e6437e9c1c4376bde8ed1b |
| institution | Matheson Library |
| issn | 2311-3006 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Cancer Research and Practice |
| spelling | doaj-art-9dd59809a1e6437e9c1c4376bde8ed1b2025-07-05T07:28:49ZengWolters Kluwer Medknow PublicationsJournal of Cancer Research and Practice2311-30062025-04-01122576210.4103/ejcrp.eJCRP-D-25-00007Tailored Management of Advanced Esophageal Squamous Cell Carcinoma — Balancing Efficacy and Toxicity with a “Hold Chemotherapy and Keep Immunotherapy” Strategy: A Case ReportYu-Chieh LinJeng-Shiun DuChun-Chieh WuEsophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with a poor prognosis in advanced stages. Pivotal trials including ATTRACTION-3, CheckMate 648, and CheckMate 577 have demonstrated that immunotherapy with nivolumab significantly improved survival and maintained disease control. We report a 59-year-old female with a 3-month history of intermittent nausea, vomiting, and unintentional weight loss of approximately 5 kg. A definite diagnosis of ESCC with distant lymph node metastasis (cT2N3M1, Stage IVB) was confirmed by positron emission tomography and esophagogastroduodenoscopy with biopsy. This report details her clinical course, including chemotherapy, immunotherapy, and radiation therapy. Despite initially achieving complete remission, recurrence was detected during follow-up. A ”Hold Chemotherapy and Keep Immunotherapy” strategy effectively managed advanced ESCC, balancing efficacy and toxicity while preserving quality of life.https://journals.lww.com/10.4103/ejcrp.eJCRP-D-25-00007esophageal squamous cell carcinomaimmunotherapymaintenance therapy |
| spellingShingle | Yu-Chieh Lin Jeng-Shiun Du Chun-Chieh Wu Tailored Management of Advanced Esophageal Squamous Cell Carcinoma — Balancing Efficacy and Toxicity with a “Hold Chemotherapy and Keep Immunotherapy” Strategy: A Case Report Journal of Cancer Research and Practice esophageal squamous cell carcinoma immunotherapy maintenance therapy |
| title | Tailored Management of Advanced Esophageal Squamous Cell Carcinoma — Balancing Efficacy and Toxicity with a “Hold Chemotherapy and Keep Immunotherapy” Strategy: A Case Report |
| title_full | Tailored Management of Advanced Esophageal Squamous Cell Carcinoma — Balancing Efficacy and Toxicity with a “Hold Chemotherapy and Keep Immunotherapy” Strategy: A Case Report |
| title_fullStr | Tailored Management of Advanced Esophageal Squamous Cell Carcinoma — Balancing Efficacy and Toxicity with a “Hold Chemotherapy and Keep Immunotherapy” Strategy: A Case Report |
| title_full_unstemmed | Tailored Management of Advanced Esophageal Squamous Cell Carcinoma — Balancing Efficacy and Toxicity with a “Hold Chemotherapy and Keep Immunotherapy” Strategy: A Case Report |
| title_short | Tailored Management of Advanced Esophageal Squamous Cell Carcinoma — Balancing Efficacy and Toxicity with a “Hold Chemotherapy and Keep Immunotherapy” Strategy: A Case Report |
| title_sort | tailored management of advanced esophageal squamous cell carcinoma balancing efficacy and toxicity with a hold chemotherapy and keep immunotherapy strategy a case report |
| topic | esophageal squamous cell carcinoma immunotherapy maintenance therapy |
| url | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-25-00007 |
| work_keys_str_mv | AT yuchiehlin tailoredmanagementofadvancedesophagealsquamouscellcarcinomabalancingefficacyandtoxicitywithaholdchemotherapyandkeepimmunotherapystrategyacasereport AT jengshiundu tailoredmanagementofadvancedesophagealsquamouscellcarcinomabalancingefficacyandtoxicitywithaholdchemotherapyandkeepimmunotherapystrategyacasereport AT chunchiehwu tailoredmanagementofadvancedesophagealsquamouscellcarcinomabalancingefficacyandtoxicitywithaholdchemotherapyandkeepimmunotherapystrategyacasereport |